Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia
NCT ID: NCT00036088
Last Updated: 2006-07-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
530 participants
INTERVENTIONAL
2001-08-31
2002-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Olanzapine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. You must have been diagnosed with schizophrenia
3. You must be able to visit the doctor's office as scheduled for the next 7 months
Exclusion:
1. You have a serious medical illness, such as heart, liver, or kidney disease (Note: If you are uncertain about a particular condition, discuss it with your doctor.)
2. You are either pregnant or breastfeeding
18 Years
75 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eli Lilly and Company
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
El Centro, California, United States
Glendale, California, United States
Sherman Oaks, California, United States
Middleton, Connecticut, United States
Norwich, Connecticut, United States
Melbourne, Florida, United States
Miami, Florida, United States
Atlanta, Georgia, United States
Chicago, Illinois, United States
Hoffman Estates, Illinois, United States
Lafayette, Indiana, United States
Rockville, Maryland, United States
Newton, Massachusetts, United States
Saint Charles, Missouri, United States
New York, New York, United States
Olean, New York, United States
Staten Island, New York, United States
Cincinnati, Ohio, United States
Portland, Oregon, United States
Philadelphia, Pennsylvania, United States
Austin, Texas, United States
El Paso, Texas, United States
Houston, Texas, United States
Terrell, Texas, United States
Richmond, Virginia, United States
La Plata, Buenos Aires, Argentina
Godoy Cruz, Mendoza Province, Argentina
Buenos Aires, , Argentina
Ciudad de Buenos Air, , Argentina
Graz, , Austria
Innsbruck, , Austria
Linz, , Austria
Wein, , Austria
Wels, , Austria
Salvador, Estado de Bahia, Brazil
Aparecida de Goiânia, Goiás, Brazil
Pelotas, Rio Grande do Sul, Brazil
Sau Paulo, Sau Paulo, Brazil
Rio de Janeiro, , Brazil
Essen, , Germany
Hamburg, , Germany
Tübingen, , Germany
Dublin, , Ireland
Mexico City, , Mexico
Lima, , Peru
Cidra, , Puerto Rico
Ponce, , Puerto Rico
Rio Piedras, , Puerto Rico
San Juan, , Puerto Rico
Barcelona, Barcelona, Spain
San Boi de Llobregat, Barcelona, Spain
Elizondo, Navarre, Spain
Pamplona, Navarre, Spain
Langreo, Principality of Asturias, Spain
Camberwell, London, United Kingdom
London, London, United Kingdom
Kings Lynn, Norfolk, United Kingdom
Paisley, Scotland, United Kingdom
Guildford, Surrey, United Kingdom
Caracas, , Venezuela
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Liu-Seifert H, Ascher-Svanum H, Osuntokun O, Jen KY, Gomez JC. Change in level of productivity in the treatment of schizophrenia with olanzapine or other antipsychotics. BMC Psychiatry. 2011 May 17;11:87. doi: 10.1186/1471-244X-11-87.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
F1D-MC-HGHJ
Identifier Type: -
Identifier Source: secondary_id
2347
Identifier Type: -
Identifier Source: org_study_id